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Type 2 diabetes mellitus (T2DM) is a chronic disease that has reached the levels of a
global epidemic. In order to achieve optimal glucose control, it is often necessary to
rely on combination therapy of multiple drugs or insulin because uncontrolled glucose
levels result in T2DM progression and enhanced risk of complications and mortality.
Several antihyperglycemic agents have been developed over time, and T2DM phar-
macotherapy should be prescribed based on suitability for the individual patient's
characteristics. Pharmacogenetics is the branch of genetics that investigates how
our genome influences individual responses to drugs, therapeutic outcomes, and inci-
dence of adverse effects. In this review, we evaluated the pharmacogenetic evidences
currently available in the literature, and we identified the top informative genetic var-
iants associated with response to the most common anti‐diabetic drugs: metformin,
DPP‐4 inhibitors/GLP1R agonists, thiazolidinediones, and sulfonylureas/meglitinides.
Overall, we found 40 polymorphisms for each drug class in a total of 71 loci, and
we examined the possibility of encouraging genetic screening of these variants/loci
in order to critically implement decision‐making about the therapeutic approach
through precision medicine strategies. It is possible then to anticipate that when the
clinical practice will take advantage of the genetic information of the diabetic patients,
this will provide a useful resource for the prevention of T2DM progression, enabling
the identification of the precise drug that is most likely to be effective and safe for
each patient and the reduction of the economic impact on a global scale.
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Diabetes mellitus is one of the leading causes of mortality worldwide
and is a major cause of blindness, kidney failure, heart attacks, stroke,
and lower‐limb amputation.1 The number of people with diabetes has
risen from 108 million in 1980,1 to 425 million in 2017, and is still
increasing.2 Type 2 diabetes (T2DM) accounts for around 90% of all- - - - - - - - - - - - - - - - - - - - - - - - - - -
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rch and Reviews Published by Johdiabetes cases; it mainly settles because of the body's ineffective
use of insulin and inability of pancreatic β cells to compensate for
the enhanced insulin demand resulting in uncontrolled glucose
homeostasis.1,2 Over time, poor glycemic control affects several body
districts, especially blood vessels and nerves, fostering the develop-
ment and progression of neuropathies, micro and macrovascular
complications, and premature death.1- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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Summary box
For each class of oral antidiabetic drugs, we reviewed
pharmacogenetic reports supporting
• associations at GWAS level of significance;
• associations replicated in multiple studies;
• associations with nominal significance lacking
replication (supplementary material).
We collectively identified 64 genes and approximately 200
informative genetic variants. The most robust evidence to
support specific, biologically plausible, gene‐drug
interactions, reguarded
• Several members of the organic cation transporter
family (OCTs), ATM and SLC2A2 loci with MET
response;
• CYP2C9, TCF7L2, ABCC8, KCNJ11 and IRS1 loci with
SUF response;
• PPARG locus with TZDs response;
• GLP1R locus with DPP‐4 inhibitors/GLP‐1 receptor
agonists response.
2 of 20 MANNINO ET AL.Interindividual variability in therapeutic response is partly due to
genetic heterogeneity, and pharmacogenomics is the discipline that
investigates how our entire genome influences individual responses
to drugs, and more specifically, pharmacogenetics focuses on genetic
variation at a population level, and how these variants can affect
therapeutic outcomes and incidence of adverse effects.3 Pharmacoge-
netics, therefore, is a key component of the translational medicine
effort. Nowadays, genetic investigation has reached an incredible
depth of information; single nucleotide polymorphism (SNP) arrays
and Next Generation Sequencing allow the screening of common and
rare genetic variants in our genome,with an unprecedented throughput.
These instruments have already been implemented for the diagnostic
processes of pathologic phenotypes and tomodel prediction of complex
traits, through the creation of panels enriched with preselected infor-
mative targets for diagnostic and research purposes. Oddly enough,
pharmacogenetic studies on oral and injectable anti‐hyperglycemic
drugs have been piling up in the literature, but this ever‐increasing
amount of knowledge is far from being translated into clinical practice
to help define the best therapeutic choice for patients with T2DM.
The aim of this comprehensive review is to discuss pharmacogenetic
evidences published until March 2018, according to T2DM pharmaco-
therapy class (metformin [MET], sulfonylureas/glinides [SUF],
thiazolidinediones [TZDs], and GLP‐1 receptor agonists/DPP‐4 inhib-
itors), in the effort of providing a critical interpretation of existing
findings to offer an overview for their future translation. Defining
the nature of drug‐gene interactions and identifying means through
which trustworthy observations can be translated into clinical
practice settings might help decision‐making about the therapeutic
approach through precision medicine strategies, ameliorate cost‐
effectiveness of existing treatments, and reduce avoidable adverse
side effects.2 | RESEARCH METHODS
A literature search was performed using MEDLINE with the following
search terms:
(“diabetes mellitus, type 2”[MeSH Terms] OR “diabetes mellitus,
type 2”[MeSH Major Topic] OR t2 dm[Title/Abstract] OR NIDDM
[Title/Abstract] OR type 2 DM [Title/Abstract] OR type II DM [Title/
Abstract] OR (diabet*[Title/Abstract] AND (type 2[Title/Abstract] OR
type‐2[Title/Abstract] OR type II [Title/Abstract] OR non‐insulin
dependent [Title/Abstract]))) AND (“pharmacogenetics”[MeSH Major
Topic] OR “pharmacogenetics”[MeSH Terms] OR pharmacogen*[Title/
Abstract] OR “precision medicine”[MeSH Major Topic] OR “precision
medicine”[MeSH Terms] OR ((“precision”[Title/Abstract] OR
“tailored”[Title/Abstract] OR “personalized”[Title/Abstract] OR
“individualized”[Title/Abstract]) AND (“therapy”[Title/Abstract]
OR “medicine”[Title/Abstract] OR “clinical practice”[Title/Abstract])
AND (“genetics”[Title/Abstract] OR “polymorphism”[Title/Abstract]
OR “snp”[Title/Abstract] OR “gwas”[Title/Abstract] OR “genome
wide association”[Title/Abstract]))) AND “english”[Language].
Manual integration with the bibliography from the most extensive
reviews on the topic has also been carried out.3 | SUMMARY OF THE LITERATURE
3.1 | Polymorphisms affecting MET response
Metformin (MET) is the only component of the biguanides class used
in clinical practice. MET has been the first line approach for T2DM
patients of novel diagnosis for decades; it produces durable anti‐
hyperglycemic effects independently of body weight, carries a low risk
of hypoglycemia, and has robust cardiovascular safety profile. For all
these reasons, MET is the first choice treatment recommended by
guidelines and is suitable for combination therapies with all other
hypoglycemic agents. It has been showed that genetic factors
influence glycemic response to MET, with a heritability of 34% for
the absolute reduction in HbA1c, adjusted for pretreatment values
(Table 1).43.1.1 | Associations at GWAS level of significance
In the first Genome Wide Association study (GWAs) of MET response
performed in two independent subsets of the GoDART cohort and in
the UKPDS, both composed of European subjects affected by T2DM,
the C allele of rs11212617 was found to be associated with reduced
glycemic response to MET (odds ratio [OR] for the ability to achieve
a treatment HbA1c <7% in the 18 months after starting MET = 1·35
95% CI 1·22‐1·49).5 rs11212617 is located downstream the gene
coding for the ATM serine/threonine kinase, associated with ataxia
telangiectasia. After discovery, the researchers were able to link ATM
to MET action through functional studies in vitro.5 Although the
TABLE 1 Summary of genetic variants that influence metformin therapy outcomes in at least one ethnic group
†Gene ‡SNP ‡Alleles ‡Region
‡Start Position
(bp) Function Associated Traits Adverse effect References
Associations at GWAS level of significance
ATM rs11212617 C/A 11q22.3 108412434 Intron MET response 5, 6
SLC2A2 rs8192675 A/G 3q26.2 171007094 Intron MET response 10
Associations replicated in multiple studies
SLC22A2 rs316019 G/T 6q25.3 160249250 Missense Ala270Ser MET PK, HbA1c MET tolerance 40, 41,
43‐47,
50
rs145450955 G/A 160250619 Missense Thr201Met MET PK, HbA1c,
FPG, HOMA‐IR
rs201919874 C/T 160250625 Missense Thr199Ile MET PK
rs3119309 C/T 160264040 Intron MET response,
MET PKrs7757336 G/T 160268526
rs2481030 A/G 160335403 Intergenic
IRS1 rs1801278 G/A 2q36.3 226795828 Missense Gly972Arg Secondary failure 15‐17
SLC22A1 rs34447885 C/T 6q25.3 160121976 Missense Ser14Phe MET PK 20, 21,
23‐27,
31‐35,
37, 38,
40
rs1867351 A/G 160122091 Synonymous Ser52Ser MET PK, HbA1c,
PPG
rs12208357 C/T 160122116 Missense Arg61Cys MET PK MET tolerance
‐ C/A 160122224 Missense Gln97Lys
rs200684404 C/T 160122285 Missense Pro117Leu
rs4709400 C/G 160122578 Intron FPG, PPG
rs34104736 C/T 160132282 Missense Ser189Leu MET PK
rs756787089 C/T 160132332 Missense Arg206Cys
rs36103319 G/T 160132375 Missense Gly220Val
rs4646277 C/T 160136228 Missense Pro283Leu
rs2282143 C/T 160136611 Missense Pro341Leu
rs34130495 A/G 160139792 Missense Gly401Ser
rs628031 G/A 160139813 Missense Met408Val MET response,
FPG
Hypoglycemia,
MET tolerance
rs72552763 ‐/GAT 160139851 inframe_indel
Met420del
MET PK MET tolerance
rs36056065 ‐/ GTAAGTTG 160139876 Intron
rs622342 C/A 160151834 Intron MET response
rs34059508 A/G 160154805 Missense Gly465Arg MET PK
rs2297374 C/T 160154953 Intron HbA1c, FPI
SLC47A1 rs77630697 G/A 17p11.2 19542448 Missense
Gly64Asp
MET PK 26‐28,
30, 48,
51‐54,
58‐60
rs77474263 C/T 19548051 Missense Leu125Phe
rs35646404 C/T 19549655 Missense Thr159Met
rs2289669 G/A 19560030 Intron MET PK, MET
response,
HbA1c
‐ C/T 19560195 Missense Ala310Val MET PK
rs149774861 A/C 19560249 Missense Asp328Ala
rs35790011 G/A 19560278 Missense Val338Ile
rs8065082 C/T 19561878 Intron HbA1c, MET response
rs76645859 G/A 19572813 Missense Val480Met MET PK
rs35395280 G/T 19577330 Missense Cys497Phe
SLC47A2 rs34399035 C/T 17p11.2 19681658 Missense Gly429Arg HbA1c 26, 55,
57, 59,
61, 62
rs373244724 T/C 19706671 Missense Tyr273Cys MET PK
rs562968062 C/A 19707841 Missense Gly211Val
rs146901447 G/A 19712704 Missense Pro162Leu MET PK, MET
response
‐ C/G 19713960 Missense Pro103Arg MET PK
‐ C/A 19715149 Missense Lys64Asn
rs12943590 G/A 19716685 5’ UTR MET PK, MET
response
rs34834489 T/A 19716951 upstream_gene MET PK
rs758427 T/C 19717164 Intron
†HUGO approved gene symbols.
‡dbSNP record from build 147/GRCh38/hg38 (where available); http://www.ncbi.nlm.nih.gov/snp/
Abbreviations: FPI, fasting plasma insulin; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; MET, metformin; PD, pharmacodynamics; PK, phar-
macokinetics; PPG, postload or 2‐h OGTT plasma glucose.
MANNINO ET AL. 3 of 20genetic association was confirmed through a meta‐analysis of five
cohorts from the United Kingdom and The Netherlands,6 more
recently, no significant differences in MET's effects by rs11212617
genotype on diabetes incidence or change in insulin sensitivity, fastingglucose levels, HbA1c, or disposition index were observed either in
the large randomized control trial Diabetes Prevention Program
(DPP) carried out in individuals with impaired glucose tolerance
(IGT)7 or in smaller studies.8 It is possible that the latter population
4 of 20 MANNINO ET AL.studies failed to replicate the original findings because of inadequate
statistical power or pharmacogenetic MET‐response interaction with
rs11212617 may diverge at different stages of impaired glucose
metabolism. In addition to this, more recently, enhancer assays of
MET‐activated epigenetic sites showed increased enhancer activity
in the ATM intron containing SNPs in LD with rs11212617.9 Interest-
ingly, the LD block encompasses several genes including EXPH5
(Exophilin 5, involved in exosome secretion and intracellular vesicle
trafficking) and DDX10 (DEAD‐box helicase 10), which resulted upreg-
ulated by MET in vitro, while ATM expression was unchanged.9
In a meta‐analysis performed by the Metformin Genetics
(MetGen) Consortium comprising 10 557 participants of European
ancestry, a genome‐wide statistically significant association was found
for the intronic SNP rs8192675, located within SLC2A2, which
encodes the GLUT2 glucose transporter.10 Each copy of rs8192675
C allele was associated with a greater MET‐induced HbA1c reduction
of 0·17% (P = 6·6 × 10−14), which was attenuated after adjusting for
baseline HbA1c (reduction of 0·07%; P = 2 × 10−8). Consistent with
the functional relevance of this variant, the C allele was associated
with lower expression of GLUT2 in the liver. However, there was no
effect of rs8192675 on the efficacy of MET in delaying progression
to diabetes in the DPP study, again raising the possibility that
MET × gene interaction in the prediabetic condition might change
when T2DM is established.
3.1.2 | Associations replicated in multiple studies
Insulin signalling is triggered by the binding of insulin to the insulin
receptor (IR). This activates the IR intrinsic tyrosine kinase activity
and promotes tyrosine phosphorylation of IR substrate (IRS) proteins,
which serve as a docking station for downstream signal
transducers.11,12 The most frequent IRS1 variant is rs1801278
(Gly972Arg),11-13 and the Arg972 allele is associated with early onset
of T2DM;14 IRS1 Gly972Arg polymorphism was found to be
associated with failure to oral hypoglycemic treatment, mostly MET
and SUF, in three Italian case‐control studies.15-17 The relationship
between Gly972Arg and efficacy of MET in lowering HbA1c was
explored in a small sample of Caucasian T2DM patients, and it
returned no significant associations.18
The Organic CationTransporter 1 (OCT1), encoded by SLC22A1 is
the main transporter of MET, and highly polymorphic in humans,19 and
several non‐synonymous variants modulate MET entrance into target
cells. Polymorphism rs628031 (Met408Val) is the only variant
identified in all ethnic groups, Europeans, South Americans, Africans,
and Asians.19 Although no associations were found with treatment
efficacy in a small European cohort of T2DM patients, carriers of the
minor allele (Met408) had a slightly reduced incidence of hypoglyce-
mic events during a 6 months period of combined MET‐SUF
treatments.20 The variant Met408 and its closely related proxy
rs36056065 (8 BP insertion) were shown to predispose to the occur-
rence of symptoms of MET intolerance in another small cohort of
T2DM patients from Latvia.21 Earlier studies had proposed Met408Val
as predictor for MET treatment efficacy, but genotype/phenotype
association has not been consistent across studies.8,22-24 In a small
case‐control study performed on Chinese subjects, the 408Val allele(the “nonrisk” allele) resulted homozygous in nine out of the 10
patients whose HbA1c declined by less than 1% after 3 months of
MET treatment.25 Polymorphism rs62234226 is the only intronic vari-
ant identified in all ethnic groups, with the exception of Pacific
Islanders,19 and has been proposed as negative predictor for MET
treatment outcomes.23,24 In a European cohort study,27 the C allele
was associated with greater HbA1c reduction in diabetic subjects
treated with MET, but this interaction could not be replicated in other
cohorts of similar ethnicity (American‐European population28,29 and
Central European drug naïve T2DM patients).30 Indeed, in a study
carried out in 122 newly diagnosed, treatment naive T2DM patients
from South India, carriers of the rs622342 C variant were found to
be less responsive to MET action on HbA1c.31 In a small clinical trial
on patients with castration‐resistant prostate cancer, homozygous car-
riers of the rs622342 C variant showed lower‐MET‐related toxicity
and reduced drug efficacy on prostate cancer progression compared
with A allele carriers.32 Caucasian, African, and South American popu-
lations share the presence of two variants: rs12208357 (Arg61Cys)26
and a deletion of the methionine codon in position 420, which can
be induced by any of three polymorphisms: rs35191146‐/G,
rs35167514‐/ATG, and rs72552763‐/TAG.19,26 Earlier studies in non-
diabetic Caucasian subjects have shown altered MET pharmacokinet-
ics and lower transport in the presence of the SNPs rs12208357
(Arg61Cys), rs34130495 (Gly401Ser), rs72552763 (Met420del), and
rs34059508 (Gly465Arg)26,33-35; while, more recently, there was no
effect on the pharmacokinetics of MET in patients carrying the
supposed reduced‐function OCT1 allele at Arg61Cys, Gly401Ser,
Met420del or Gly465Arg.36 The same polymorphisms, together with
the SLC22A1 promoter‐linked synonymous variant rs1867351
(Ser52Ser), were associated with an increase in the renal clearance
of MET, possibly driven by a reduction in OCT1 expression or activ-
ity.37 Similarly, in a small cohort of EuropeanT2DM patients, the num-
ber of OCT1 reduced‐function alleles in Arg61Cys and Met420del was
significantly associated with two‐fold higher odds of the common
MET‐induced gastrointestinal side effects38; nevertheless, a large ran-
domized control trial performed on Scottish subjects (GoDART) and a
large‐scale meta‐analysis on subjects of European ancestry (MetGen)
showed no clinically evident reduction in the ability of MET to lower
HbA1c in individuals withT2DM in presence of the variants Arg61Cys
and Met420del.29,39 A small case‐control study performed on Chinese
T2DM subjects, depicted peculiar phenotype patterns for Ser52Ser
and two intronic polymorphisms, rs4709400 and rs2297374.25
Ser52Ser‐affected HbA1c and postprandial plasma glucose response
to MET, rs4709400 affected both fasting and postprandial glucose
MET modulation, and rs2297374 modulated HbA1c and fasting insulin
levels.25 Experimental studies have demonstrated that
OCT1‐mediated MET uptake is reduced in oocytes expressing
rs2282143 (Pro341Leu) and rs4646277 (Pro283Leu).40 Pro341Leu is
highly frequent in the Asiatic population; a trend toward higher MET
bioavailability was reported in Korean subjects, although it was not
statistically significant, and the analyses were not corrected for
possible confounders.41 Of much rarer distribution, the following
variants have only been assayed in vitro: rs34104736 (Ser189Leu)
and rs36103319 (Gly220Val) have been involved with reduced MET
transport, rs34447885 (Ser14Phe) was shown to increase MET
MANNINO ET AL. 5 of 20uptake,33 and cells expressing the extremely rare mutation Gln97Lys,
rs200684404 (Pro117Leu), or rs756787089 (Arg206Cys) had reduced
MET uptake and pharmacokinetics.24
SLC22A2 encodes the Organic Cation Transporter 2 (OCT2),
which has strong affinity for MET.42 The intergenic variants
rs3119309, rs7757336, and rs2481030 located between SLC22A2
and SLC22A3 within a linkage block, have been recently associated
with the lack of response to MET in a small group of Caucasian
patients with T2DM and reduced levels of circulating MET in carriers
of the risk alleles.43 Three nonsynonymous variants, rs145450955
(Thr201Met), rs316019 (Ala270Ser), and rs201919874 (Thr199Ile),
were repeatedly shown to influence MET uptake, tubular excretion
and clearance, consistent with an increase in circulating MET
concentrations, both in vitro and in vivo.40,41,44-47 Among Iranian
T2DM patients treated with MET, carriers of 201Met exhibited
higher‐HbA1c concentrations, fasting glucose levels, and homeostasis
model assessment of insulin resistance (HOMA‐IR), and a possible sex
specificity, which had never been reported previously.48 In a small
number of Chinese T2DM patients of novel diagnosis, a significantly
stronger decrease in HbA1c was observed in heterozygous compared
with wild‐type 270Ala homozygous after 1 year of treatment with
MET, upon adjustment for baseline HbA1c, exercise, and diet.47 No
effects of Ala270Ser on MET pharmacokinetics or pharmacodynamics
were detected in a small group of nondiabetic Korean subjects.49
Ala270Ser exhibited no genotype/phenotype association when
studied in Caucasian subjects.28-30,37
Notably, in 2013, it has been suggested that interaction with
variants in the multidrug and toxin extrusion (MATE) 1 transporter
(SLC47A1) may mask SLC22A2 Ala270Ser effects on MET clearance.50
Several studies performed in European subjects have identified an
association between the intronic variants of SLC47A1 rs2289669
and rs8065082 (closely in linkage disequilibrium) and response to
MET in subjects withT2DM.26,28,51 Individuals who were homozygous
for SLC22A1 rs622342C allele exhibited a larger‐MET glucose‐
lowering effect, which was exacerbated in presence of one or two
SLC47A1 rs2289669A alleles.27,51,52 rs2289669A by itself was associ-
ated with greater HbA1c decline in newly diagnosed T2DM patients
of Chinese,53 Iranian,54 and European30 ethnicity. Newly diagnosed
Chinese T2DM patients and healthy Koreans carrying the
rs2289669A allele exhibited lower‐MET excretion and renal
clearance.49,53 However, rs2289669 showed no association with
MET clearance in studies performed in Caucasian nondiabetic37 and
T2DM patients,29,55 independently of SLC22A1 rs622342
genotype.29,55 Using knockout experiments on mice, it has been
revealed that alterations of SLC47A1 sequence on both chromosomes
are required in order for MET to accumulate in the liver, fostering
lactic acidosis.56,57 It is, then, likely that inconsistencies about the
effects of rs2289669 and rs622342 might depend on other, more
dramatic, mutations of SLC47A1, occurring at an independent site,
such as the five nonsynonymous variants, identified in a multiethnic
nondiabetic cohort, associated with reduced MET transport
in vitro58-60: rs77630697 (Gly64Asp), rs77474263 (Leu125Phe),
rs35790011 (Val338Ile), rs76645859 (Val480Met), and rs35395280
(Cys497Phe).58 Additionally, three nonsynonymous variants were
demonstrated to be associated with reduced MET transport in vitro:rs149774861 (Asp328Ala), the extremely rare mutation Ala310Val,
and rs35646404 (Thr159Met) exclusive of Asiatic populations.59,60
SLC47A2 encodes for the transporter MATE2, highly homologous
to MATE1, and, as the latter, is involved in excretion of endogenous
and exogenous toxic electrolytes through urine and bile. Several
non‐synonymous variants in SLC47A2 sequence exhibited reduced
MET transport activity in vitro: The transcript in presence of the rare
mutations Lys64Asn,59 rs562968062 (Gly211Val),57,59 and
rs146901447 (Pro162Leu)57 were not detectable in engineered
HEK293 cells, while Tyr273Cys was localized to the wrong cellular
compartments.57 By contrast, the variant Pro162Leu seemed to
increase the response to MET in vivo in a cohort of African American
subjects.61 The rare mutation Pro103Arg was found to be correctly
expressed at the plasma membrane and to overdouble MET transport
activity.57 Finally, rs34399035 (Gly429Arg) was the only
nonsynonymous variant apparently affecting the long‐term decrease
in HbA1c in European Caucasians, with carriers of the variant showing
a 0·8% (95% CI, 0·02‐1·6; P = 0.05) lower decrease than the wild‐type
carriers.55 The intronic polymorphism rs12943590 was associated
with reduced clinical response to MET in US diabetic subjects of
African or European ancestry.26,61 The non‐coding variant
rs12943590, in the 5' UTR, was found to induce no pharmacokinetic
differences in Koreans41 and in a large meta‐analysis performed on
European T2DM subjects;29 nevertheless, a small group of Korean
nondiabetic volunteers carrying rs12943590 or rs758427 and
rs34834489 exhibited increased promoter activity, with a significant
raise in renal and secretion clearance.62
3.1.3 | Associations with nominal significance lacking
replication (supporting information)3.2 | Polymorphisms affecting SUF/meglitinides
response
For years, the drug of choice alongside MET has belonged to the
family of SUF/glinides. Both pharmaceutic classes carry weight gain
as side effect and a high risk of hypoglycemia.63 SUF bind the ATP‐
dependent K+ (KATP) channels on beta‐cells membrane therefore
inducing K+ entrance into the cell, the depolarization of the plasma
membrane, and the opening of voltage‐gated Ca2+ channels. The spike
of intracellular Ca2+ levels triggers insulin zymogen fusion with the
plasma membrane and insulin secretion. Over time, the compensatory
efforts of the beta cells may eventually lead to a decline of beta‐cell
mass and secondary failure of sulfonylurea/glinides treatment
(Table 2).64
3.2.1 | Associations replicated in multiple studies
The gene CYP2C8 encodes for an enzyme belonging to the
cytochrome P450 (CYP) superfamily. In presence of the most diffused
dyplotype, CYP2C8*3, defined by the variants rs11572080
(Arg139Lys) and rs10509681 (Lys399Arg), repaglinide metabolism
was reported to be increased,65,66 resulting in reduced drug bioavail-
ability.67 By contrast, the frequency of CYP2C8*3 carriers was
TABLE 2 Summary of genetic variants that influence sulfonylureas/meglitinides therapy outcomes in at least one ethnic group
†Gene ‡SNP ‡Alleles ‡Region
‡Start Position
(bp) Function Associated Traits Adverse Effect References
Associations replicated in multiple studies
CYP2C8 rs10509681 (*3) T/C 10q23.33 95038992 Missense Lys399Arg SUF PK 65‐67
rs11572080 (*3) G/A 95067273 Missense Arg139Lys
CYP2C9 rs1799853 (*2) C/T 10q23.33 94942290 Missense Arg144Cys SUF PK Hypoglycemia 68‐82, 87
rs1057910 (*3) A/C 94981296 Missense Ile359Leu
SLCO1B1 rs4149015 G/A 12p12.1 21130388 Upstream gene Repaglinide response 65, 72, 82‐95
rs4149056 T/C 21178615 Missense Val174Ala SUF PK
ABCC8 rs757110 T/G 11p15.1 17396930 Missense Ala1369Ser SUF response 82, 96‐98,
100‐103,
108, 109
rs1799859 G/A 17397732 Synonymous
Arg1273Arg
SUF response, TG
rs1801261 C/T 17415318 Synonymous
Thr759Thr
SUF response
rs1799854 C/T 17427157 Intron SUF response, TG
KCNJ11 rs5210 G/A 11p15.1 17386704 3’ UTR SUF response 26, 97, 103,
116‐121rs5219 C/T 17388025 Missense Lys23Glu Secondary failure
KCNQ1 rs2237892 C/T 11p15.4 2818521 Intron Repaglinide response 127‐129
rs163184 T/G 2825839 SUF response, FPG
rs2237895 A/C 2835964 Repaglinide response
NOS1AP rs10494366 G/T 1q23.3 162115895 Intron SUF response Mortality 131, 132,
134rs12742393 A/C 162254796 Repaglinide response,
FPG, FPI, HbA1c
IRS1 rs1801278 G/A 2q36.3 226795828 Missense Gly972Arg SUF response, insulin
secretion
Secondary failure 15, 18, 20,
135, 136
TCF7L2 rs7903146 C/T 10q25.2 112998590 Intron SUF response Secondary failure 142‐144
rs12255372 G/T 113049143
rs290487 C/T 10q25.3 113149972 Repaglinide response
†HUGO approved gene symbols.
‡dbSNP record from build 147/GRCh38/hg38 (where available); http://www.ncbi.nlm.nih.gov/snp/
Abbreviations: FPG, fasting plasma glucose; FPI, fasting plasma insulin, HbA1c, glycated haemoglobin; PK, pharmacokinetics; SUF, sulfonylureas/
meglitinides; TG, triglycerides.
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enced hypoglycemic events while undergoing treatment with SUF
(glimepiride, gliclazide, or glipizide) in respect to wild‐type CYP2C8*1
homozygous subjects, but this difference was not statistically signifi-
cant.68 The closely related CYP2C9 enzyme is the major responsible
for SUF breakdown. The non‐synonymous variants rs1799853
(Arg144Cys) and rs1057910 (Ile359Leu), respectively defined as
CYP2C9*2 and CYP2C9*3, have been reported to determine lower‐
CYP2C9 catalytic activity,69-72 resulting in reduced SUF clearance
and higher‐drug bioavailability across different ethnicities.70,73-79 Of
notice, these evidences translate into increased odds of moderate to
severe hypoglycemic events during treatment with SUF.68,80-82 How-
ever, CYP2C9*2 and *3 have been shown not to carry increased risk of
hypoglycemia in healthy volunteers and T2DM patients taking
glimepiride, glibenclamide, gliquidone,69,78,83,84 or nateglinide.72,85
Caution should be advised when interpreting these data because it
has been recently demonstrated that CYP2C9 catalytic impairment
might be counteracted by the effects of genetic variation at the CYP
oxidoreductase (POR) gene, which is tightly associated with CYP
enzymes and can modulate their activity;86 indeed, in a subset of
subjects from the GoDART database, it has been reported that the
number of CYP2C9*2 and *3 alleles was associated with nearly
three‐fold increased risk of hypoglycaemic events and better response
to SUF only in patients carrying the POR*1/*1 wild‐type genotype.87
The solute carrier organic anion transporter 1B1 (SLCO1B1)
encodes for a transmembrane receptor protein, called OATP1B1,involved in the removal of anionic compounds from the blood into
the hepatocyte. SLCO1B1 locus is highly polymorphic; its best charac-
terized non‐synonymous variant, rs4149056 (Val174Ala), has been
demonstrated to significantly increase repaglinide bioavailability in
both T2DM and healthy subjects of Caucasian and Asian ethnic-
ity.65,88-93 A larger concentration of nateglinide in the presence of
the low‐metabolizing variant 174Ala has also been reported,72,94 but
the association has not been consistent throughout other studies.89,91
The non‐coding SNP rs4149015, located less than 1 kb upstream
SLCO1B1 has been found to be associated with an increased
glucose‐lowering effect of repaglinide,65 an effect that could be attrib-
uted to the close proximity with rs4149056 polymorphism.95
The ABCC8 gene encodes for a member of the superfamily C of
ATP‐binding cassette (ABC) transporters, which functions as a modu-
lator of KIR6.2 transporters (encoded by KCNJ11), and together, they
form KATP channel complexes. Several SNPs within the ABCC8 locus
have been associated to interindividual variability in the response to
SUF treatment. The intronic polymorphism rs1799854 (exon 16 −3C
➔ −3 T), often combined with the closely linked non‐synonymous
variant rs1801261 (Thr759Thr),26 has been associated with reduced
insulin secretion after tolbutamide infusion in nondiabetic relatives
of T2DM patients.96 T2DM patients on SUF treatment carrying the
rs1799854C/C genotype exhibited significantly lower‐HbA1c levels
compared with the patients with T/T genotype and improved insulin
sensitivity determined by HOMA index in response to repaglinide,
with respect to T carriers.97,98 However, rs1799854 was not
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performed on a small cohort of T2DM patients.99 T2DM patients on
SUF treatment carrying the G/G genotype of the synonymous SNP
rs1799859 (Arg1273Arg) had significantly higher‐HbA1c levels
compared with the patients with A/A genotype,98 thus implying
lower‐SUF efficacy. In the same study, no effect of rs757110
(Ala1369Ser) was observed on SUF ability to modulate either fasting
and postprandial glucose levels or HbA1c.98 The latter result has been
confirmed in several studies across different ethnicities.82,100,101 ten
combined with theNevertheless, in two studies, both performed on
Chinese T2DM patients, homozygous carriers of the 1369Ala allele
were reported to exhibit enhanced glicazide efficacy.102,103 The ability
of ABCC8 polymorphism Ala1369Ser to interfere with SUF therapy is
peculiarly controversial because this SNP is in strong linkage
disequilibrium with the non‐synonymous variant Lys23Glu in
KCNJ11,104,105 and it is possible to postulate the existence of a
molecular selective specificity for the genetic variation at KATP
channels.106 Indeed, when compared with ABCC8‐KCNJ11wild‐type
haplotype carriers, 1369Ala‐23Lys haplotype was shown to increase
sensitivity to gliclazide, and mitiglinide,106,107 whereas it was less
responsive to tolbutamide, chlorpropamide, and glimepiride,106 and
no differences have been observed with the use of nateglinide,
repaglinide, glipizide, and glibenclamide.84,106,107 Finally, both ABCC8
polymorphisms rs1799854 and rs1799859 resulted associated with
circulating triglycerides level after SUF therapy.108,109
KCNJ11 (potassium voltage‐gated channel subfamily J member
11) encodes for the pore forming subunit (also named KIR6.2) of the
KATP channel designated to modulate glucose‐dependent insulin
secretion in pancreatic beta cells. Large studies have been able to
prove that the non‐synonymous polymorphism rs5219 (Lys23Glu)26
is more frequent inT2DM102,105,110-112 and in subjects with decreased
insulin secretion,113 although initial reports documented no associa-
tion between genetic variants in KCNJ11 and T2DM.104,109,114,115 In
vitro experiments in human pancreatic islets have demonstrated a
reduction in response to SUF in presence of the non‐synonymous
polymorphism 23Lys,116 which has been confirmed in studies
performed on T2DM patients of Chinese ethnicities undergoing SUF
therapy,117 alongside the nearby non‐coding variant rs5210.26,103
Consistent with the previous observations, 23Lys carriers have been
reported to exhibit higher predisposition to secondary failure when
treated with SUF.116,118-120 By contrast, studies performed on T2DM
patients of Caucasian121 and Asian97 descent have observed a positive
effect of the variant 23Lys in response to SUF or no significant
differences in the glucose lowering action of the drug.98,111 The risk
of hypoglycemic events commonly associated with SUF therapy has
been found to be independent from the presence of the Lys23Glu
variant122 or its non‐synonymous proxy rs5215 (Val337Ile).82
The KCNQ1 gene, located on chromosome 11, belongs to a large
family of voltage‐gated K+ channels. The intronic variant rs2237895 in
KCNQ1 has been found to be associated with reduced insulin secre-
tion in cross‐sectional and prospective studies, conferring increased
T2DM risk across different ethnicities.123-126 The intronic polymor-
phisms rs2237892 and rs2237895 were shown to increase repaglinide
sensitivity,127,128 whereas a third intronic variant, rs163184, was
reported to lower‐SUF effects on fasting plasma glucose levels.129The gene NOS1AP encodes for the nitric oxide synthase (NOS) 1
adaptor protein, which downregulates the neuronal NOS1 and Ca2+
influx channels. The SNP rs10494366 in the NOS1AP gene has been
associated with QTc prolongation.130 In the Rotterdam study, a
population‐based cohort study of elderly people, carriers of the TG
or GG genotype at rs10494366 treated with glibenclamide exhibited
higher‐glucose levels and mortality rates compared with glibenclamide
users with the TT genotype.131 In addition, in Chinese patients with
T2DM, the TT genotype was associated with an increased effect of
repaglinide on insulin resistance measured by HOMA index.132 By
contrast, pharmacodynamics studies carried out in Korean healthy
volunteers showed no statistically significant differences based on
rs10494366 genotype.84 The intronic variant rs12742393 has been
associated withT2DM in a cohort of Chinese patients with the C allele
showing significant risk for diabetes with an OR of 1·17 (95% CI, 1·07‐
1·26, P = 0.0005).133 Indeed, the effects of repaglinide treatment on
fasting plasma glucose, insulin levels, and HOMA‐IR index were
reduced in patients withT2DM carrying the NOS1AP rs12742393 risk
C allele compared with carriers of the AA genotype.134
As anticipated in Section 3.1.2, IRS1 plays a pivotal role in the
transduction of the insulin signalling cascade. The most frequent vari-
ant of IRS1, Gly972Arg, was found to be associated with failure of the
hypoglycemic treatment with SUF in five case‐control studies.15-18,120
Furthermore, diabetic patients carrying the Arg972 variant receiving
treatment with insulinotropic hypoglycaemic drugs such as SUF
and/or glinides had higher‐HbA1c levels compared with wild‐type car-
riers.18 In vitro experiments performed on a rat beta‐cell line and iso-
lated human islets have proven that the risk allele 972Arg is associated
with a marked reduction of insulin secretion in response to SUF.135,136
The locus of transcription factor 7‐like 2 gene (TCF7L2) is the
strongest known signal associated with T2DM.137 Consistent
evidences have been reported for the intronic polymorphisms of
TCF7L2 (rs12255372 and rs7903146) with increased risk of
T2DM.138-141 Both risk alleles have also been associated to reduced
response to SUF treatment in a large randomized control trial on Euro-
pean subjects,142 and rs7903146 polymorphism was associated to
SUF treatment failure in an independent study on T2DM German
patients.143 A pharmacogenetic study in Asian subjects has assessed
the effects exerted on glimepiride hypoglycemic efficacy by several
intronic variants in the TCF7L2 locus, in a small number of healthy
volunteers84; the SNPs rs290487, rs11196205, and rs12255372,
along with rs7903146, showed no differences when compared with
the wild‐type alleles,84 although the variant rs290487 had previously
been identified as a modulator of repaglinide therapeutic action in
Chinese T2DM patients.144
3.2.2 | Associations with nominal significance lacking
replication (supporting information)3.3 | Polymorphisms affecting TZDs response
Since the late 1990s, TZDs are a therapeutic option for patients with
T2DM in whom they act by improving insulin sensitivity and preserv-
ing β‐cell secretory function. The net effect of TZDs is an increased
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decreased lipolytic activity, resulting in decreased free fatty acids con-
centration and improved adipocytokine profile.145 Similarly to SUF
and insulin treatment, TZDs may lead to weight gain, partly because
of TZDs' most common side effect, fluid retention, which might foster
the formation of peripheral edema in patients with cardiac or renal dis-
ease.146 Because of the potential for long‐term adverse effect, TZDs
use has been subject of debate with one molecule in this class,
troglitazone (TRO) being taken off‐market since the year 2000,
because of increased incidence of drug‐induced hepatitis and
rosiglitazone (ROSI) being suspected of bringing cardiovascular harm
and retracted by the Food and Drug Administration at first, but later,
it has been restored in the US market.147 Pioglitazone (PIO) is the only
TZD still marketable in Europe, and it has actually been reported to
improve cardiovascular events in patients with T2DM and in insulin
resistant nondiabetic individuals (Table 3).148-150
3.3.1 | Associations replicated in multiple studies
Multiple cytochrome P450 enzymes are involved in the metabolism of
TZDs; however, CYP2C8 (previously discussed in Section 3.2.1) is
responsible for the catalysis of most of the biotransformation of PIO
and ROSI.66,151-155 Its most frequent haplotype is CYP2C8*3, mainly
found in Caucasians and Hispanics, designated by the presence of
two non‐synonymous polymorphisms: rs11572080 Arg139Lys and
rs10509681 Lys399Arg.155,156 Carriers of CYP2C8*3 were shown to
have significantly lower‐ROSI area under the curve (AUC), higher‐oral
clearance,157 lower OR of developing edema,158 and a statistically
significant reduced response to ROSI treatment,158,159 although one
early study in a very small cohort detected no association of
CYP2C8*3 with the drug glucose‐lowering effect.160 CYP2C8*3
polymorphisms were shown to reduce PIO AUC as well, resulting in
higher‐PIO clearance.161-164 CYP2C8*11, identified by the presence
of the infrequent nonsense variant rs78637571 Glu274Stop in
subjects of East Asian ethnicity, was reported to increase ROSI AUCTABLE 3 Summary of genetic variants that influence thiazolidinediones
†Gene ‡SNP ‡Alleles ‡Region
‡Start Position
(bp) Func
Associations replicated in multiple studies
CYP2C8 rs10509681 (*3) C/T 10q23.33 95038992 Misse
rs78637571 (*11) C/A 95045951 Stop
rs11572103 (*2) A/T 95058349 Misse
rs11572080 (*3) A/G 95067273 Misse
PPARG rs1801282 C/G 3p25.2 12351626 Misse
PPARGC1A rs8192678 A/G 4p15.2 23814039 Misse
rs2970847 C/T 23814301 Syno
ADIPOQ rs266729 C/G 3q27.3 186841685 Upst
rs2241766 A/C 186853103 Syno
rs1501299 G/T 186853334 Intro
†HUGO approved gene symbols.
‡dbSNP record from build 147/GRCh38/hg38 (where available); http://www.n
Abbreviations: FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; PIO
TZDs, thiazolidinediones.and bioavailability in heterozygous subjects.165 Finally, the polymor-
phism rs11572103 Ile269Phe, designated as CYP2C8*2, has been
reported to influence PIO pharmacokinetics in vivo in African
Americans.166
PPARG is a nuclear receptor serving as lipid sensor and the cognate
receptor for TZDs167; its most common variant, rs1801282 (Pro12Ala),
reproducibly associated with decreased risk of T2DM,168-171 has been
widely addressed in pharmacogenetics studies on TZDs efficacy. Sev-
eral reports have been meta‐analysed revealing a better response to
PIO treatment in terms of improvements in fasting glucose, HbA1c
and triglycerides in carriers of the 12Ala allele164,172-174 despite two
studies observed no association,175,176 and one reported that insulin
levels and insulin resistance were lower in carriers of the Pro12Pro
genotype after PIO treatment.172 In response to ROSI, Korean T2DM
patients carrying the 12Ala variant have been shown to have
significantly greater decrease in fasting glucose levels and HbA1c.177
Earlier studies evaluating how the common genetic variation in PPARG
influenced TRO efficacy have revealed a nominal association for
multiple SNPs,178 but several smaller and larger study groups failed at
replicating the previously reported associations.175,179,180
The docking of PPARG to the transcription factor coactivator
PPARGC1A allows the recruitment of two transcription factors to form
a highly efficient transcription complex. In ChineseT2DM patients, the
non‐synonymous polymorphisms (Thr394Thr; rs2970847 and
Gly482Ser; rs8192678) in PPARGC1A appear to influence patient
response to ROSI therapy.158,173,181 To date, no significant differences
were observed when the effects of Gly482Ser were evaluated in
patients treated with PIO.173
ADIPOQ encodes the anti‐inflammatory cytokine adiponectin,
solely expressed in adipose tissue. The variant rs266729, located
approximately 1 kb upstream ADIPOQ has been shown to induce
greater changes in fasting glucose and HbA1c after treatment with
PIO in a study conducted in Chinese T2DM patients,182 and carriers
of the homozygous wild‐type rs266729 genotype, undergoing
treatment with ROSI, exhibited a greater reduction in fasting plasmatherapy outcomes in at least one ethnic group
tion Associated Traits Adverse Effect References
nse Lys399Arg TZD PK Edema 157‐159,
161‐166gained Glu274Stop ROSI PK Hypoglycemia
nse Ile269Phe PIO PK
nse Arg139Lys TZD PK, ROSI
response
Edema
nse Pro12Ala TZD response,
FPG, HbA1c,
TG
164, 172‐174,
177
nse Gly482Ser ROSI response 158, 173, 181
nymous Thr394Thr
ream gene TZD response,
FPG, HbA1c
182‐184, 186
nymous Gly15Gly
n ROSI response,
FPG, HbA1c
cbi.nlm.nih.gov/snp/
, pioglitazone; PK, pharmacokinetics; ROSI, rosiglitazone; TG, triglycerides;
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from Southern China has shown that the synonymous T45G polymor-
phism at rs2241766 (Gly15Gly) is related to PIO response in T2DM
with patients carrying the TG genotype exhibiting a greater reduction
in HbA1c,184 whereas no evidence of pharmacogenetic influence on
HbA1c or fasting glucose levels was observed in response to PIO
treatment in Iranian T2DM patients.185 Together with rs2241766
polymorphism, the intronic SNP rs1501299 has been shown to be
associated with reduced fasting glucose and HbA1c levels after ROSI
therapy,186 while opposing evidences were reported in a large cohort
of Chinese patients in which the therapeutic efficacy of multiple‐dose
ROSI was assessed.183
3.3.2 | Associations with nominal significance lacking
replication (supporting information)3.4 | Polymorphisms affecting DPP‐4
inhibitors/GLP‐1 receptor agonists response
Dipeptidyl peptidase 4 (DPP‐4) inhibitors and glucagon like peptide 1
(GLP‐1) receptor (GLP‐1R) agonists are considered effective options
to lower glucose levels because they carry moderate to low risk ofTABLE 4 Summary of genetic variants that influence DPP‐4 inhibitors/G
†Gene ‡SNP ‡Alleles ‡Region
‡Start Position
(bp) Func
Associations at GWAS level of significance
GIPR rs13306399 C/G 19q13.32 45670699 Miss
rs13306398 G/T 45674785 Miss
rs13306403 G/T 45677928 Miss
rs1800437 C/G 45678134 Miss
rs10423928 A/T 45679046 Intro
QPCTL rs2287019 C/T 45698914 Intro
GLP1R rs10305420 C/T 6p21.2 39048860 Miss
rs3765467 C/T 39065819 Miss
rs367543060 C/T 39066240 Miss
rs6923761 A/G 39066296 Miss
rs10305492 A/G 39079018 Miss
rs10305493 C/G 39079155 Miss
Associations replicated in multiple studies
KCNQ1 rs151290 A/C 11p15.4 2800385 Intro
rs2237892 C/T 2818521
rs163184 C/A 2825839
rs2237895 A/C 2835964
rs2237897 C/T 2837316
TCF7L2 rs7903146 C/T 10q25.2 112998590 Intro
rs12255372 G/T 113049143
†HUGO approved gene symbols.
‡dbSNP record from build 147/GRCh38/hg38 (where available); http://www.n
Abbreviations: BMI, body mass index; CVD, cardiovascular disease; DPP‐4I, DP
PPG, postload or 2‐h OGTT plasma glucose; PPI, postload 2‐h OGTT plasma inhypoglycemia, thus offering better life‐quality expectancies to the
patients. Because the incretin hormones GLP‐1 and GIP (gastric inhib-
itory polypeptide) are rapidly cleaved into the bloodstream by DPP‐4
into inactive forms, DPP‐4 inhibitors have been developed to increase
circulating incretins level, for the treatment of T2DM.187 GLP‐1R ago-
nists, by definition, explicate their function by triggering the GLP‐1R
cascade.188-190 Adverse effects induced by GLP‐1R agonists include
transient nausea, vomiting, and diarrhoea,191 although prescription to
patients with a history of pancreatitis, medullary thyroid carcinoma,
and multiple endocrine neoplasia syndrome type 2 should be made
with caution (Table 4).192
3.4.1 | Associations at GWAS level of significance
Although several naturally occurring non‐synonymous polymorphisms
in the gene coding for gastric inhibitory polypeptide receptor (GIPR)
have been characterized, the polymorphism rs13306399 (Cys46Ser)
was the only one capable of altering the binding of GIP,193 while both
rs13306399 and rs13306403 (Arg316Leu) have been shown to
decrease GIP sensitivity in beta cells in vitro.193 The same
polymorphisms, together with the infrequent variants rs13306398
(Gly198Cys) and rs1800437 (Glu354Gln), are also associated with
reduced cell surface expression and basal receptor signalling.193LP1R agonists therapy outcomes in at least one ethnic group
tion Associated Traits
Adverse
effect References
ense Cys46Ser GIP sensitivity, GIP
expression
193‐196,
198, 199
ense Gly198Cys GIPR expression
ense Arg316Leu GIP sensitivity, GIP
expression
ense Glu354Gln GIPR expression CVD
n GIP response, PPG,
PPI, BMI,
Osteopontin, GIPR
expression
n FPG, PPG 198, 201
ense Pro7Leu Liraglutide response 197, 203‐210,
214‐216ense Arg131Gln GLP1 response
ense Thr149Met
ense Gly168Ser Liraglutide response,
DPP4i response,
PPG, BMI
ense Ala316Thr FPG, PPG, PPI
ense Ser333Cys GLP1R binding
n Incretin response,
GLP‐1 levels, PPI
123‐126,
219‐221
Incretin response, PPI
DPP‐4I response
Incretin response, PPI
n GLP1 response,
DPP‐4I response,
Hb1Ac
221,225–227
GLP1 response
cbi.nlm.nih.gov/snp/
P‐4 inhibitors; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin;
sulin.
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disease incidence194 and cultured adipocytes carrying the rs1800437
minor C allele manifested a drastic downregulation of the receptor
desensitization‐resensitization cycle.195 The A allele of the intronic
variant rs10423928 was associated with a lower amount of the splic-
ing isoform required for transmembrane activity.196 Recently a
6 months follow‐up study carried out in a small group of T2DM
patients found no evidence of association with DPP‐4 inhibitors effi-
cacy,197 although carriers of the A allele had been reported to exhibit
0·09 (CI, 0·07‐0·11) mmol/L increase of 2‐h postload glucose levels
during an OGTT, decreased insulin secretion, and a diminished incretin
effect in vivo in large cohort studies,198,199 aside of a reduction in
body mass index (BMI), lean body mass, and waist circumference.199
A molecular connection with osteopontin (OPN) was suggested
because carriers of rs10423928 had lower‐OPN expression in pan-
creas and adipose tissue, both GIP and OPN modulate cytokine‐
induced apoptosis.196,199 The intron variant rs2287019, falling within
the glutaminyl‐peptide cyclotransferase‐like (QPCTL) gene, approxi-
mately 15 kb downstream GIPR, has been associated with BMI at
genome‐wide level.200 The risk C allele was also reported to be
associated with higher fasting glucose but lower 2‐h postload glucose
concentrations during an OGTT.198,201 Taken together, these findings
suggest that GIPR variants could potentially modulate the response to
DPP‐4 inhibitors, nevertheless, to date, this effect has not been
revealed by clinical studies.194,197,202
The GLP‐1 receptor is an important drug target for the treatment
of T2DM, and several non‐synonymous variants of GLP1R have been
carefully characterized: rs367543060 Thr149Met variant, identified
in one Japanese diabetic subject,203 induces a significant loss of func-
tion in vitro204-206 and impairs the insulin secretory response to GLP‐
1 in vivo.203,206 The polymorphism rs10305493 (Ser333Cys) instead
has been proven to preserve peptide response.205,206 The SNP
rs6923761 (Gly168Ser) was nominally associated with reduced insu-
lin secretion in response to GLP‐1 infusion during a hyperglycemic
clamp in nondiabetic American subjects207 and with a weaker
response to the glucose‐lowering effect of DPP‐4 inhibitors in
patients with T2DM.197 On the contrary, the same polymorphism
was associated with higher efficacy of liraglutide,208 and it was
shown to increase weight and fat mass loss after liraglutide treat-
ment,209,210 different types of diet,211 or bilio‐pancreatic diversion
surgery.212 In addition, carriers of the rs6923761 A allele had higher
basal GLP‐1 levels210 and a better cardio‐metabolic profile.213 When
the dyplotype rs6923761 (Gly168Ser)/rs10305420 (Pro7Leu) was
studied, the wild‐type form 7Pro, combined with the mutated
168Ser appeared to give an even bigger contribution to the efficacy
of treatment with liraglutide.208 Heterozygous carriers of the minor
allele of rs3765467 (Arg131Gln) were reported to have higher beta‐
cell response to GLP‐1 infusion during a hyperglycemic clamp,207
but no significant differences were observed when genotypes at
rs3765467 and rs761386 (an intronic variant in perfect linkage dis-
equilibrium with the intronic short tandem repeat at rs5875654
8GA/7GA) were compared in relation to changes in plasma glucose
levels after exenatide treatment. Finally, the minor (A) allele of the
low‐frequency rs10305492 (Ala316Thr) was associated at genome‐
wide level with lower fasting glucose levels,214-216 and lower risk ofT2DM, but lower early insulin secretion and higher 2‐h glucose
during an OGTT.216
3.4.2 | Associations replicated in multiple studies
As anticipated in Section 3.2.1, KCNQ1 channels are involved not only
with the mechanisms of insulin secretion but also in GLP‐1 and GIP
release from the intestinal endocrine cells.217 In a small pilot study,
KCNQ1 polymorphisms rs163184 G was associated with lower‐HbA1c
reduction in response to DPP4 inhibitors treatment,218 consistent
with previous findings in European,125 South American,126 and
Asian123,124 subjects. rs2237895, rs151290, rs2237892, and
rs2237897, all falling within the same intron as rs163184, were found
to be associated with several OGTT‐derived indexes of insulin
secretion, although not during the intravenous glucose tolerance test
(IVGTT), in nondiabetic subjects.219 Regardless, nondiabetic individ-
uals homozygous for the diabetes protective allele (A) at rs151290
exhibited lower‐active GLP‐1 concentrations at 10 minutes during
the OGTT.220
AlthoughTCF7L2 (previously addressed in Section 3.2.2) has been
suggested to regulate proglucagon gene expression, and thus GLP‐1
synthesis in intestinal L cells,221-223 no significant variation in the
concentration of GLP‐1 was observed in carriers of different
genotypes of the risk variant rs7903146.220,223,224 Results reporting
impaired insulin secretion in response to GLP‐1 infusion rather
suggested that two variants (rs7903146, rs12255372) in TCF7L2
might reduce GLP‐1 action on beta cells.224,225 In support of the latter
theory, reduction in HbA1c in response to 24 weeks of treatment with
the DPP‐4 inhibitor linagliptin was reportedly attenuated in homozy-
gous carriers of the risk allele rs7903146 T.226 Nevertheless, other
studies have observed no rs7903146 attributable differences in
GLP‐1‐induced beta‐cell responsiveness.220
3.4.3 | Associations with nominal significance lacking
replication (supporting information)4 | CONCLUSIONS
Although the development of T2DM is clearly associated with a famil-
ial history of diabetes with a heritability estimated at 30%‐70%,227 the
current set of about 100 established susceptibility loci with robust
association signals, identified primarily through large‐scale GWAS,
captures only 10% of familial aggregation of the disease.228,229 Disap-
pointingly, although the identification of such a large number of novel
susceptibility loci has opened up the opportunity to translate this
genetic information into the improvement of T2DM risk prediction,
the available data suggest that genetic screening is currently of little
value in clinical practice with risk variants adding very little to the
predictive power provided by clinical risk factors alone.230 In addition
to this, we are unaware of how most of those susceptibility loci
contribute to diabetes incidence, especially in the case of non‐coding
polymorphisms or genes that do not translate into proteins; therefore,
we are yet incapable of exploiting them as drug targets for functional
intervention on the disease.
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interindividual variability in the response to oral and injectable
glucose‐lowering agents, and in recent years, many pharmacogenetic
studies of associations between genetic variants and glucose‐lowering
drug response have been published. To a large extent, these studies
were designed to identify subsets of subjects more or less likely to
experience therapeutic response to the drug in question or to develop
side effects. Indeed, the care of patients with T2DM requires an indi-
vidualized approach because of the fact that the disease is heteroge-
neous, alterations in molecular and pathophysiological pathways of
glucose homeostasis differ between subjects, and the variable effects
of existing therapies make it difficult to predict individual response to
glucose‐lowering medications.231 Clearly, an individualized approach is
important because of the multitude of clinical features involved in
decision‐making including age, body weight, disease duration, life
expectancy, glycemic control history, risk of hypoglycemia, adverse
effects of glucose‐lowering medications, presence of complications
and comorbid conditions, and psycho‐socio‐economic factors.232,233
Througout this review, it was definetly shown how ethnicity is also a
major determinant of the outcomes.234-236 The usual approach for
T2DM therapy comprises the stepwise addition of medications to
lifestyle interventions, usually beginning with a single oral drug
and advance to combination therapy, followed by the addition or
substitution of insulin, based on the progressive failure of the
medications to maintain adequate glucose control. In the context of
personalized or precision medicine, pharmacogenetic information
may be useful for patient stratification in order to identify responders
and to balance the benefits of glucose‐lowering medications with
their potential risks.
Testing few genetic markers may be a relatively straightforward
method to evaluate the above‐mentioned biologic factors, keeping in
mind that the individual genetic asset is independent from the time
point of the disease course; thus, it can reveal information that would
otherwise be disguised by the disease itself.
In this comprehensive review, we attempted collecting all the
literature on the pharmacogenetics of diabetes medications. Although
it is recognized that interindividual variability in therapeutic response
is partly due to genetic heterogeneity, the pharmacogenetic studies
herein reported have shown no consistent results. For instance,
although there is evidence that genetic factors influence up to 34%
of the glycemic response to MET,4 the combined effect of the ATM
and SLC2A2 loci on MET response has been shown to be minimal,
suggesting that other genetic determinants of MET response remain
to be revealed. Moreover, a recent Danish study, carried out in a
population‐based cohort predominantly treated with MET (55%), has
investigated the influence of 48 T2DM susceptibility variants on
disease progression assessed as early redemption of either a
glucose‐lowering drug or an insulin drug prescription. Results have
shown that common T2DM‐associated gene variants do not signifi-
cantly affect disease progression requiring additional therapies.237
Several issues can be highlighted about the design of most of the
studies evaluated for this review. It is important to note that none of
the published studies was a prospective randomized clinical trial
specifically conceived to unravel pharmacogenetic associations. Such
approach would be able to limit selection bias and confoundingfactors, especially if performed on large‐scale cohorts. Instead, we
collected several observational, cross‐sectional, or retrospective stud-
ies, mostly with a small sample size, devoid of the discovery power
required to identify smaller effect sizes. Many studies have investi-
gated the effects of genotypes on a single‐medication intervention
without including a placebo or a control group. Therefore, it is not
possible to exclude that these studies have reported the effect of
genotype rather than the modification of the response to the
medication. In addition, most studies did not address the issue of
multiple comparisons, so that it is possible that the reported findings
are false positives. Many associations were only assayed in a single
study (supporting information), which most of the time did not
include enough details to judge the rigorousness of the research.
Moreover, a number of studies did not report on testing for
Hardy‐Weinberg proportions and on masking of genotyping person-
nel. Furthermore, genotyping calls obtained with probes or restriction
fragment length analysis were rarely confirmed by sequencing. With
few exceptions, the authors adopted the candidate gene approach,
which raises the concern of selective reporting of results and publica-
tion bias. Overall, the reported effect size of genetic variants on
glucose‐lowering drug response is small and, in many cases, clinically
meaningless.
Notably, we should always assume the presence of the “winner
curse” because of the overestimation of the effect size of a newly
identified genetic association, when the statistical power of the
discovery study is not sufficient to detect the true OR of smaller
magnitude or when positive results are reported and null results are
not. As a consequence, winner curse implies that the power required
to independently confirm the association will be underestimated,
resulting in failure of replication. This type of bias cannot be resolved
by meta‐analyses since the heterogeneity of pharmacogenetic studies,
by itself, precludes comparisons within outcomes and quantitative
synthesis with meta‐analyses. In addition to this, most findings were
only confirmed in one ethnicity. Although each population with its
unique genetic and social fingerprint differs from the others in allele
frequencies, it would be expected that a specific, biologically
supported interaction between gene and drug would be conserved
across different ethnicities.
Finally, most of the studies available in the literature have only
focused on the effects of a single site on drug efficacy, but researchers
have already begun evaluating the joint contribution of T2DM‐related
loci.238
In order to account for such heterogeneity, this review groups the
results in the following categories: associations at GWAS level of
significance, associations replicated in multiple studies, and associa-
tions with nominal significance lacking replication. With this outline,
we have been able to identify 64 genes and approximately 200
informative genetic variants. Keeping in mind the above described
limitations of the studies, some reports seem to provide robust
evidence to support specific, biologically plausible, gene‐drug interac-
tions. The most robust evidence seem to support a role for variants in
OCTs, ATM, and SLC2A2 loci with MET response, CYP2C9, TCF7L2,
ABCC8, KCNJ11 and IRS1 loci with SUF response, PPARG locus with
TZDs response, and GLP1R locus with DPP‐4 inhibitors/GLP‐1
receptor agonists response.
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The incorporation of pharmacogenetic information into clinical prac-
tice in the context of personalized medicine cannot occur without
the results of well‐designed studies proving significant gene‐drug
interactions. The technology of genetic investigations has reached
formidable levels nowadays; commercial probe‐based SNP array
platforms can now genotype, with greater than 99% accuracy, about
one million SNPs at the same time per individual in one assay.
Next‐generation sequencing can deliver the same information that
SNP arrays can produce but with greater resolution and accuracy
and the possibility to extend the approach from target SNPs to
target genes. Furthermore, next generation sequencing can uncover
structural DNA modifications that SNP arrays do not resolve. Cost‐
wise, the machinery required for signal detection of SNP arrays and
next generation sequencing might appear impractical for immediate
applications. Nevertheless, it is widely recognized that diabetes
imposes an important economic burden on national healthcare
system, with the most drainage deriving from hospital inpatient
care after the onset of micro/macrovascular complications. An
additional healthcare cost is related to the therapeutic failure of
drugs as well as serious adverse side effects of drugs on individuals.
It is possible then to anticipate that when the clinical practice will
take advantage of the genetic information of the diabetic patients,
this will provide a useful resource for the prevention of T2DM
progression and the personalization of treatment enabling the
identification of the precise drug that is most likely to be effective
and safe for each patient, and the reduction of the economic impact
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